Rezolute
Specializing in the development of drug therapies for patients with metabolic and orphan diseases.
Launch date
Employees
Market cap
AUD449m
Enterprise valuation
AUD329m (Public information from Sep 2024)
Share price
$4.82 RZLT
Louisville Kentucky (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | - | 16.4m | 22.7m |
% growth | - | - | - | - | - | - | 38 % |
EBITDA | (20.3m) | (22.3m) | (41.5m) | (51.8m) | - | - | - |
Profit | (20.3m) | (20.9m) | (41.1m) | (51.8m) | (63.0m) | (57.3m) | (72.7m) |
% profit margin | - | - | - | - | - | (349 %) | (320 %) |
EV / revenue | - | - | - | - | - | 11.9x | 8.0x |
EV / EBITDA | -1.3x | -5.3x | -2.6x | -1.4x | - | - | - |
R&D budget | 14.5m | 15.0m | 32.5m | 43.8m | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$12.0m | Post IPO Equity | ||
N/A | $6.7m | Post IPO Equity | |
* | N/A | $5.0m | Convertible |
* | $25.0m | Post IPO Equity | |
$41.0m | Post IPO Equity | ||
$30.0m | Post IPO Debt | ||
N/A | $55.0m | Post IPO Equity | |
* | N/A | $130m | Private Placement VC |
* | N/A | $6.7m | Post IPO Equity |
* | N/A | $60.0m | Post IPO Equity |
Total Funding | AUD209m |
Related Content
Recent News about Rezolute
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.